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Executive Summary 
 Methamphetamine is a drug of abuse, which is often produced in clandestine laboratories. 
Recent efforts to curb methamphetamine abuse are aimed at controlling access to precursors, 
including pseudoephedrine (PSE), used in illicit methamphetamine production. Currently, access 
to PSE is controlled in Kentucky by placement behind pharmacy counters, retail quantity 
limitations and electronic tracking. Recent legislation proposed in Kentucky to change PSE from 
non-prescription to a legend medication was unsuccessful and highly controversial. The 
objective of this project is to collect and analyze pharmacists’ opinions on the effectiveness of 
current precursor controls, proposed legislation to make PSE a legend drug and impact on their 
practice and patients.  
 This research has been approved by the University of Kentucky Institutional Review 
Board and utilizes survey methodology to obtain opinions of Kentucky pharmacists regarding the 
recent proposed legislation to make PSE a legend drug. Survey questions included perceived 
efficacy of current precursor controls, anticipated impact on individual pharmacy practice and 
patients and current opinion in regards to the proposed legislation. For this project, all surveys 
were conducted anonymously with no identifying information collected. A simple random 
sample of pharmacists (n=2000) was drawn from a list of all licensed pharmacists in the 
Commonwealth of Kentucky, excluding pharmacists with an out-of-state practice address. The 
survey response rate was 30.6%. Pharmacists practicing in a hospital or “other” setting were 
excluded from the analysis, as their practice sites are not directly impacted by PSE sales. The 
final group for analysis included 431 pharmacists practicing in a chain or independent 
community pharmacy setting.  
Descriptive statistics were generated, including frequencies and proportions. Bivariate 
analyses were conducted using the Chi-squared test and t-test. Multivariate logistic regression 
was performed to investigate the impact of independent variables on pharmacists’ support of or 
opposition to the legislation to make PSE available by prescription-only. Independent variables 
utilized in the regression model include: chain versus independent pharmacist status, anticipated 
impact of making PSE prescription-only on time spent on PSE-related activities and pharmacy 
profits, Kentucky region of pharmacy practice, anticipated impact of making PSE prescription-
only on methamphetamine abuse and laboratory incidents, confidence in identifying patients 
utilizing PSE for a legitimate medical purpose and grams of PSE sold per county resident. 
 The 2012 Pseudoephedrine Survey for Pharmacists showed that 56.2% of Kentucky 
pharmacists practicing in a community pharmacy support the proposed legislation to make PSE 
available by prescription-only, 30.7% oppose the legislation and 13.1% are unsure. Furthermore, 
independent and chain pharmacists significantly differ in the average number of prescriptions 
filled per day, number of PSE purchases per day and the number of years in practice. Practice 
site significantly impacts support for the proposed legislation with chain pharmacists being 2.90 
times more likely to support the legislation to make PSE prescription-only. One possible 
explanation for this difference is that independent pharmacists may exhibit more autonomy in the 
decision making process to sell or not sell PSE to potential customers. Additional factors that 
influence pharmacist support of the legislation include: anticipated impact of making PSE 
prescription-only on time spent on PSE-related activities and pharmacy profits, Kentucky region 
of pharmacy practice, and anticipated impact of making PSE prescription-only on 
methamphetamine abuse and laboratory incidents. Kentucky region of pharmacy practice 
appears to have a large impact on pharmacist support of the legislation. Regions, such as 
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western, eastern, and southern Kentucky, associated more strongly with methamphetamine 
appear to more strongly support the proposed legislation.  
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Background 
Methamphetamine Overview 
Description of Methamphetamine and History 
Methamphetamine is a synthetically produced stimulant medication belonging to the 
amphetamine group, which results in activation of the brain. Amphetamines, including 
methamphetamine, were widely available in the United States without a prescription until 1951. 
During the 1960s, methamphetamine became widely abused and diverted following use as 
treatment for heroin addiction.
1
 Drug users began injecting methamphetamine intravenously and 
obtaining the drug through black markets. In 1971, methamphetamine was rescheduled as a 
Schedule II controlled substance by the Drug Enforcement Administration (DEA), which 
resulted in an immediate reduction in abuse and diversion.
1
  
In the 1980s, ephedrine and pseudoephedrine (PSE) were approved by the Food and Drug 
Administration (FDA) as nasal decongestants for over-the-counter (OTC) use, and shortly after 
the approval, resurgence in methamphetamine abuse was observed. Ephedrine and PSE are two 
precursor ingredients used in illicit methamphetamine production in clandestine laboratories.
2
 
Today methamphetamine is recognized as medical treatment, available by prescription, for 
narcolepsy, attention deficit disorder, attention deficit hyperactivity disorder, depression and 
obesity.
1
 However, given the significant associated risks and adverse effects of 
methamphetamine, alternative therapies are generally preferred and medical use of 
methamphetamine remains extremely limited. 
Methamphetamine Abuse  
According to the United Nations Office on Drugs and Crime (UNODC) World Drug 
Report 2012, Methamphetamine abuse affected between 14 and 53 million people or 0.3-1.2% of 
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the worldwide population in 2010.
3
 Methamphetamine can be taken through a variety of routes 
including swallowing orally, smoking, snorting or injecting intravenously. The most common 
means of illicit methamphetamine use in the United States is through snorting or intravenous 
injection.
1
  
Methamphetamine produces an initial euphoric ‘rush’, which often prompts the user to 
continue using methamphetamine. After continued use of methamphetamine, anorexia, weight 
loss, insomnia, aggression, hallucinations, paranoia, convulsions, stroke, cardiac arrhythmia, and 
hyperthermia may occur.
2
 As chronic abuse occurs, irreversible brain and heart damage, memory 
loss, psychotic behavior, rages, violence and ultimately the inability to care for oneself and one’s 
children is often observed.
2
 In addition to the known physical and emotional harms associated 
with methamphetamine abuse, methamphetamine production is associated with significant 
harms.    
Methamphetamine Production and Description of Pseudoephedrine  
Prior to the 1971 rescheduling as a Schedule II controlled substance, methamphetamine 
was primarily obtained through the black market, which consisted of diverted supplies from 
pharmaceutical companies, distributors and physicians.
1
 Upon the rescheduling, illicit 
methamphetamine laboratories began emerging. Initially, methamphetamine was produced using 
two organic compounds, phenyl-2-propanone (“P2P”) and methylamine, as precursor chemicals.
4
 
Motorcycle gangs manufactured and distributed methamphetamine beginning in San Francisco 
and spreading along the Pacific Coast and then moving westward.
4
 
In 1980, phenyl-2-propanone became a Schedule II controlled substance, and 
manufacture shifted towards using OTC ephedrine and PSE as chemical precursors to produce 
methamphetamine through a reduction method.
4
 The reduction method proved to be simpler and 
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led to a more potent form of methamphetamine. Today, the DEA estimates that more than 80% 
of methamphetamine in the United States comes from clandestine “super” labs in Mexico and 
California, which are operated by Mexican drug trafficking organizations.
1
 The remaining 20% 
of methamphetamine in the United States is reported to come from small, amateur, clandestine 
laboratories.
1
 Small quantities of methamphetamine are relatively easy and cheap to manufacture 
and little knowledge, skill or equipment is necessary. However, small-scale, clandestine 
laboratories are extremely dangerous due to the nature of the volatile chemicals used in the 
manufacturing process.
1
 Fires, explosions and environmental contamination are common.
1
 
Laboratory seizures have been reported in a wide range of locations, including “sleeping areas, 
kitchens and eating areas where food is prepared and stored, garages, vehicles, hotel and motel 
rooms, storage lockers, mobile homes, apartments, ranches, campgrounds, rural and urban 
dwellings, abandoned dumps, restrooms, houseboats, and other locations” which represents a 
large public safety concern.
1
 According to the DEA National Seizure System, a record number of 
methamphetamine laboratory seizures was reported in 2010 and the number of seizures has 
increased steadily since 2005, as shown in Figure A.
5
   
 
 
 
 
 
 
 
 
8 
 
Figure A. Reported Methamphetamine Laboratory Seizures in the United States, by Capacity, 
2005-2010
  
Source: U.S. Department of Justice National Drug Intelligence Center, National Drug Threat 
Assessment 2011
5
 
 
Today, amateur, clandestine laboratories obtain PSE largely through a process called 
“smurfing”. Federal legislation restricts the amount of PSE that may be purchased OTC by an 
individual (see Methamphetamine Precursor Control Legislation below). In order to circumvent 
the quantity limitation of PSE, a group of individuals is paid “to go from store to store making 
purchases of products containing pseudoephedrine or ephedrine under the threshold 
requirements…this process was and is repeated day after day in store after store”.
6
 Furthermore, 
the individuals evade any logbook or electronic system by using various forms of identification.  
Methamphetamine Precursor Control Legislation 
Federal Laws 
A series of federal laws have been enacted in order to control access to methamphetamine 
precursor chemicals. Federal methamphetamine precursor laws have been aimed at increasing 
reporting and record keeping requirements, requiring registration with the DEA, implementing 
packaging requirements, quantity limits, and placement behind the pharmacy counter. Federal 
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laws have targeted bulk precursor chemicals, OTC products containing PSE and combination 
products containing PSE. Table 1 summarizes the major federal laws implemented to control 
methamphetamine precursor chemicals.
2
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 Table 1. Summary of Federal Efforts to Limit Access to Methamphetamine Precursors  
Act Primary Implications Year 
Chemical Diversion and 
Trafficking Act (CDTA) 
Regulated bulk ephedrine and PSE by requiring 
record keeping, reporting requirements, and 
import/export notifications. Did not include OTC 
tablets, capsules and other products containing 
ephedrine or PSE. 
 
1988 
Domestic Chemical 
Diversion Control Act 
(DCDCA) 
Required distributors, importers and exporters to 
register with the DEA and gave the DEA power to 
revoke registration. Additionally, removed the 
record-keeping and reporting exemption for single 
entity ephedrine products. 
 
1993 
Comprehensive 
Methamphetamine Control 
Act (MCA) 
Broadened federal regulation of chemicals to 
include combination OTC medicines containing 
precursor ingredients and increased penalties for 
methamphetamine and methamphetamine precursor 
trafficking and production.  
 
1996 
Methamphetamine Anti-
Proliferation Act (MAPA) 
Established quantity restrictions for a single 
purchase of OTC medications containing ephedrine, 
PSE and phenylpropanolamine. Additionally, new 
packaging precursor quantity limitations were 
included in MAPA. 
 
2000 
Combat Methamphetamine 
Epidemic Act (CMEA) 
Included the following key requirements: 
 Quantity limit of 3.6 grams of precursor base 
(PSE) per customer per day and 9 grams per 
customer per month; 
 Store all methamphetamine precursor containing 
products behind the counter;  
 Maintain a logbook for two years containing the 
time and date of sale, name and quantity of 
product sold and name and address of each 
purchaser; 
 Require purchasers to present identification and 
sign the logbook. 
 
2005 
Combat Methamphetamine 
Enhancement Act 
Placed restriction on distributors and retailers who 
sell products used in illicit methamphetamine 
manufacture. 
 
2010 
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Multiple studies have examined the impact of early federal methamphetamine precursor 
regulations on a variety of indicators of methamphetamine use and production. A 2003 study by 
James Cunningham and Lon-Mu Liu examined the impact of four federal ephedrine and PSE 
regulations that were implemented between 1989 and 1997on methamphetamine-related hospital 
admissions in California. Three regulations focused on large-scale laboratories, while one 
regulation targeted small-scale clandestine laboratories by regulating combination ephedrine 
products. The study showed a 35-71% drop in methamphetamine-related hospital admissions 
following the implementation of each of the regulations targeting large-scale clandestine 
laboratories.
7
 However, the reduction in admissions resurged beginning 6-24 months after each 
regulation was implemented. No effect was seen following the regulation targeting small-scale 
clandestine laboratories. The study noted possible reasons for the resurgence of admissions, 
including producers accessing alternative supplies of precursors and importing precursors from 
foreign countries. 
A 2005 study by Cunningham and Liu investigated the impact of federal precursor 
chemical regulations on methamphetamine related arrests in California. The study examined the 
impact of the same four federal methamphetamine precursor regulations as the 2003 study. The 
study concluded that methamphetamine arrests stopped rising and decreased by 31-45% 
following the implementation of each of the three regulations involving large-scale producers.
7
 
However, little or no effect was seen following the implementation of the regulation involving 
small-scale producers. Additionally, arrests rebounded fully within two to three years, which is 
likely due to the fact that producers were able to circumvent regulations or the increased 
regulations pushed users into self-production.  
12 
 
A 2008 study by Cunningham and Liu examined the impact of methamphetamine federal 
precursor chemical regulations on the demand for drug treatment. The study showed a decline in 
voluntary methamphetamine treatment admissions following the precursor regulations of 1995 
and 1997 by 39% and 31%, respectively.
7
 However, the first decline rebounded within two years 
and the second rebounded within four years.  
The 2011 study conducted by Nonnemaker, Engelen and Shive examined the impact of 
retail-level methamphetamine precursor laws in reducing indicators of domestic production, 
methamphetamine availability, and consequences of methamphetamine use. The implementation 
of MAPA and a state level restriction, the California Uniform Controlled Substances Act 
(UCSA), enacted in 2000 was studied. The California UCSA further restricted precursor access 
by including all ephedrine and PSE products, regardless of packaging. The study found no 
evidence of a decrease in methamphetamine indicators following implementation of the federal 
MAPA and some evidence for the effect of the California UCSA.
8
 Overall, rises in 
methamphetamine purity and lower prices have called into question the net benefit of domestic 
precursor controls. The authors suggest that the strict domestic control of methamphetamine 
precursors may be causing unintended consequences as seen by increased supply from 
international trafficking.  
State Laws 
In addition to the federal legislation regarding methamphetamine precursor control, many 
states have enacted additional laws to further control the sale of PSE and ephedrine. A variety of 
additional methamphetamine precursor control laws have been enacted across the United States.  
13 
 
Electronic Tracking and Block of Sales 
 Following the passage of CMEA, pharmacies and retail outlets were required to maintain 
a logbook of individual PSE sales. While the logbook requirement can be effective at preventing 
excessive PSE purchasing within a single store, the legislation did not actively prevent 
purchasing PSE from multiple stores, as seen in the practice of smurfing. Multiple states have 
implemented regulations which require the electronic tracking of PSE purchases. Electronic 
tracking utilizes the purchaser’s driver’s license or alternate identification and records the date 
and amount of PSE sold. The data is stored centrally and can be shared among all stores within 
the network to prevent the purchase of PSE that would exceed the legal limit. As of July 2011, 
twenty states have passed electronic tracking laws.
2
 The most common electronic tracking 
system utilized by states is National Precursor Log Exchange (NPLEx).
2
 NPLEx is provided by 
the National Association of Drug Diversion Investigators (NADDI) free of charge, and the 
program is sponsored by manufactures of OTC PSE products.  
Purchase Quantity Restrictions 
 The 2005 CMEA restricted retail purchases of PSE to 9 grams per 30 days.
2
 However, 
five states, as of December 2011, have implemented more stringent laws restricting PSE 
purchase to between 6 and 7.5 grams per 30 days.
2
 The maximum daily dose of PSE is 240mg 
per day, which corresponds to a thirty day maximum dose of 7.2 grams. Thus, a quantity 
restriction of 7.2 grams per 30 days should not impact individuals purchasing PSE for legitimate 
uses.   
Schedule V Controlled Substance 
 As of December 2011, eleven states have reclassified PSE as a Schedule V controlled 
substance.
2
 Schedule V products are available OTC. However, additional requirements exist 
14 
 
including maintaining a log of all transactions, requirement for proof of age (18 years or older) 
and restriction to purchase in a pharmacy. Furthermore, states with prescription monitoring 
programs (PMPs) that include Schedule V controlled substances may require transmission of 
data to the PMP.  
Methamphetamine Registry/Block of Sales to those with Previous Methamphetamine-related 
Convictions 
  Oklahoma passed legislation in 2010 which requires all individuals convicted of 
possession, manufacture, distribution or trafficking of methamphetamine to register with the 
state.
2
 Additionally, the registered individuals are prohibited from purchasing and possessing 
PSE. The convicted methamphetamine registry is linked with the electronic PSE tracking system 
and blocks sales to individuals with methamphetamine-related convictions, regardless of quantity 
limitations.
2
  
Prescription-only Status/ Schedule III Controlled Substance 
 Two states, Oregon and Mississippi, have made PSE a Schedule III controlled substance 
available by prescription-only.
2
 Medications which require a prescription to dispense are often 
referred to as legend drugs. Arkansas passed legislation in 2011, which requires a prescription 
for PSE unless the purchaser can provide an Arkansas Driver’s License or ID card.
2
 
Additionally, the pharmacist must confirm medical need for individuals purchasing products 
containing PSE in Arkansas.  
The most recent 2012 study by Cunningham, et al., examined the impact of prescription-
only status of methamphetamine precursor products on clandestine laboratory seizure, an 
indicator of laboratory prevalence. Two states, Oregon (7/2006) and Mississippi (7/2010), have 
implemented regulations to classify ephedrine and PSE as Schedule III controlled substances 
15 
 
available by prescription-only.
9
 The results of the study showed that Oregon’s laboratory 
seizures were not significantly affected by the prescription regulation. However, the number of 
seizures began declining months before implementation of the regulation and remained low for 
more than five years following the prescription precursor regulation. Additionally, the same 
trends were seen in Oregon’s border states. On-the-other-hand, laboratory seizures in Mississippi 
dropped approximately 50% following prescription regulation of methamphetamine precursors, 
while nearby non-border states exhibited increases in laboratory seizures.
9
 The study suggested 
that states with more laboratory seizures, such as Mississippi, would likely benefit from 
prescription precursor regulation, while states with less laboratory seizures and more 
methamphetamine trafficking from Mexico, such as Oregon, would experience less benefit from 
prescription precursor regulation.   
A 2010 study by Hendrickson, Cloutier and Fu examined the impact of the 2006 
prescription methamphetamine precursor requirement in Oregon on methamphetamine-related 
Emergency Department (ED) visits. The results showed a 35% decrease in the number of 
methamphetamine-related ED visits from the pre-legislation period to the post-legislation 
implementation period.
10
  
In conclusion, a number of federal laws have been enacted to control access to 
methamphetamine precursors. Furthermore, many states have implemented additional legislation 
to more strictly control access to methamphetamine precursors. Multiple studies have evaluated 
the impact of federal legislation on indicators of methamphetamine abuse. Overall, the studies 
have shown an initial impact following implementation of legislation targeting large-scale 
methamphetamine production.
7,8,11,12
 However, the initial decline in methamphetamine indicators 
was followed by a rebound. Federal legislation aimed at small-scale methamphetamine 
16 
 
production has not been shown to have a significant impact on methamphetamine indicators. The 
studies evaluating the impact of state legislation on methamphetamine indicators have evaluated 
the prescription-only requirements in Oregon and Mississippi. One study showed no change in 
Oregon’s laboratory seizures while a second study showed a drop in methamphetamine-related 
ED visits in Oregon following the implementation of the prescription-only PSE requirement.
9,10
 
Additionally, the first study showed a 50% drop in laboratory seizures in Mississippi following 
the prescription-only PSE requirement and attributed the difference between Oregon and 
Mississippi to the greater number of clandestine laboratories in Mississippi and more 
methamphetamine importation from Mexico in Oregon.
9
  
Overview of the Methamphetamine Problem in Kentucky 
 According to the Report on Methamphetamine and Other Drug Use in Kentucky prepared 
by The University of Kentucky Special Commission on the Study of Methamphetamine and 
Other Emerging Drugs in Kentucky, lifetime methamphetamine use in Kentucky is estimated to 
be 2.6% of the population.
13
 The report suggests a slight national decline in methamphetamine 
use yet a rising methamphetamine problem in Kentucky. The number of laboratory seizures in 
Kentucky has risen from 428 in 2008 to 741 in 2009 and 1078 in 2010, as shown in Figure B.
14
 
Despite federal and state legislation aimed at controlling access to methamphetamine precursors, 
Kentucky manufactures have been able to find alternate methods for methamphetamine 
production and means of circumventing laws and tracking systems. Smurfing is thought to be a 
principle method for circumventing PSE quantity restrictions. Furthermore, new production 
methods, such as the “one-pot cook” method, which is also called “shake and bake”, have led to 
increased production of methamphetamine via less complicated processes. The most common 
production method in Kentucky is the “one-pot cook” method.
14
 In the “one-pot cook” method, 
17 
 
all ingredients are combined at the same time in one bottle. The “one-pot cook” method is 
particularly dangerous due to the unstable nature of the chemical reactions.
14
  
Figure B. Number of Laboratory Seizures in Kentucky 2001 to 2010 
 
Source: Kentucky State Police Report
14
 
 
Methamphetamine as a percentage of total drug cases in Kentucky has been increasing 
from 6% of total drug cases in 2007 and 2008 to 9% in 2009 and 11% in 2010.
14
 According to 
both the Report on Methamphetamine and Other Drug Use in Kentucky and the 
Methamphetamine Manufacturing in Kentucky 2010 report, methamphetamine has traditionally 
been associated with western and central Kentucky, as shown in Figure C. However, current 
trends indicate rising methamphetamine indicators in eastern Kentucky.
14
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Figure C. Methamphetamine Laboratory Seizures in Kentucky, 2009
Source: Kentucky State Police Report
14
 
 
 A recent research letter described the correlation between PSE sales and the number of 
clandestine laboratories per county in Kentucky in 2010.
15
 The results showed Kentuckians 
purchased a mean of 24,664 grams of PSE per county and 1072 laboratories were reported in 
Kentucky in 2010.
15
 A great deal of variability existed in both the amount of PSE sold and 
laboratories reported among counties. Counties with a larger number of PSE sales were 
associated with a significantly greater number of reported laboratories. The research letter 
reports a 1.7% increase in laboratories for every 1 gram increase in PSE purchased per 100 
people.
15
  
Current and Proposed Regulation of Methamphetamine Precursors in Kentucky  
 In addition to the federal regulations controlling access to methamphetamine precursors, 
Kentucky has implemented additional methamphetamine precursor regulations. Kentucky 
requires electronic tracking and block of PSE sales exceeding the legal limit. Kentucky was the 
first state to implement electronic tracking with NPLEx in 2008.
2
 Additionally, Kentucky has 
recently passed a stricter PSE quantity limit than the federal limit of 9 grams per month. As of 
July 2012, Kentucky law limits PSE monthly sales per individual to 7.2 grams.
16
 New legislation 
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also includes the creation of a methamphetamine registry for those convicted of a 
methamphetamine-related crime and blocking sales of PSE to individuals listed in the registry.
17
 
 Over the past year, a great deal of attention has been focused on the methamphetamine 
problem in Kentucky and new legislation regarding methamphetamine precursors has been 
proposed. Much controversy has been generated regarding the proposal to make PSE available 
by prescription-only.
2
 Proponents of requiring a prescription to purchase PSE argue that data 
from Oregon and Mississippi indicate efficacy in reducing the number of laboratory incidents 
and associated hazards in states with a large number of clandestine laboratories.
2
 Additional data 
show a decrease in methamphetamine-related crime, arrest and admission to substance abuse 
treatment facilities following implementation of prescription-only PSE mandates.
2
 However, 
further data are needed to ensure the reduction in methamphetamine indicators is sustained. 
Additionally, proponents of a prescription-only mandate argue that a majority of OTC PSE 
purchased is used for methamphetamine production.
2
 Proponents believe OTC PSE creates 
hazards for the public and law enforcement, which represents a large cost to society.  
 Opponents of requiring a prescription to obtain PSE reason that the mandate would place 
additional burdens on physicians, pharmacists, insurance companies and consumers.
2
 Some 
believe consumers will face additional costs and inconveniences for repeat doctor visits to obtain 
prescriptions for PSE. The Asthma and Allergy Foundation of America (AAFA), which strongly 
opposes making PSE available by prescription-only, conducted an online survey in July 2010 of 
more than 2,000 adults suffering from asthma, allergies, cold, cough or flu in the preceding 
twelve months. According to the survey, 71% of respondents oppose a law that requires a 
prescription to obtain PSE, while 66% support a nationwide e-tracking system.
18
 Most 
respondents reported opposing a law that requires a prescription to obtain PSE due to increased 
20 
 
costs, inconvenience and the thought that the law would be ineffective in decreasing 
methamphetamine abuse and target honest citizens. According to the survey, respondents prefer 
e-tracking over a prescription requirement due to efficacy and the limited burden placed on law 
abiding citizens.
18
  
An analysis of the prescription-only PSE requirement in Oregon was conducted by the 
Cascade Policy Institute and funded by a grant from the Consumer Healthcare Products 
Association (CHPA). CHPA is a not-for-profit organization which represents manufactures and 
distributors of OTC medications, and supports keeping PSE and associated products available 
OTC. Multiple studies have found methamphetamine precursor restrictions to be effective in 
reducing methamphetamine indicators, at least in the short-term.
9,10
 However, the analysis by the 
Cascade Policy Institute presents evidence of non-significant changes in methamphetamine lab 
incidents, similar decreases in treatment episodes when compared to similar states with no 
prescription requirement, and no decrease in methamphetamine-related deaths.
19
 The analysis 
also reports added time and expenses involved with additional doctor visits. Added costs could 
include the direct cost of the doctor visit, the increased cost of the drug, travel expenses and costs 
from lost time and productivity.
19
 Additionally, the article states that some patients may opt for 
less effective treatment or no treatment, which could result in a lower quality of life.  
Importance of Studying Kentucky Pharmacist Opinions of the Potential 
Reclassification of Pseudoephedrine as a Legend Drug 
 Data clearly indicate the notable problem of methamphetamine abuse and production in 
Kentucky. Methamphetamine production in clandestine laboratories appears to be increasing in 
Kentucky and represents a significant hazard and cost to society as a whole.
13,14
 While there 
appears to be consensus that something must be done to address the methamphetamine problem, 
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various solutions have been proposed with some generating a great deal of controversy; the most 
notable being the proposed prescription-only mandate for purchase of PSE. To date, quantitative 
and qualitative data are available regarding consumers’ opinions of various methamphetamine 
precursor controls.
18,19
 However, there is very limited understanding of the opinions of 
healthcare providers, specifically pharmacists, regarding methamphetamine precursor controls.  
A 2009 study interviewed twenty Australian community pharmacists-in-charge regarding 
their opinions of developments in the Australian OTC medication market, including PSE sales.
20
 
Project STOP is an electronic PSE tracking system in Australia, which consists of an online 
database that checks patient identification and recent OTC PSE purchases to support 
pharmacists’ determination of the legitimacy of PSE requests. According to the study, Australian 
pharmacists deemed Project STOP to be very useful in preventing misuse and abuse of PSE.
20
 
However, some pharmacists reported concern over robberies due to illicit methamphetamine 
manufacturers being unable to obtain PSE through legal means. Other concerns about the 
program included challenges in pharmacists’ workloads and strained relationships with patients.  
Community/retail pharmacists and staff are often busy entering prescriptions into the 
computer system, clarifying prescriptions with physicians, verifying patient allergies, checking 
for potential drug interactions, processing insurance claims, calling insurance companies to 
resolve issues, ensuring the correct medication, dosage, strength and quantity is dispensed to the 
patient, and counseling patients on disease states and medications. The processing of OTC PSE 
purchases interrupts the pharmacy workflow and requires a pharmacy staff member to stop his or 
her current task, obtain customer identification, start the electronic tracking program, enter 
customer identification information and information about the product the customer is wishing to 
purchase, submit the information and wait for the tracking system to respond with the 
22 
 
recommendation to dispense or not dispense the PSE. If numerous PSE purchases are requested 
daily, a non-trivial amount of time can be spent dispensing PSE and result in a significant 
interruption in the pharmacy workflow. Thus, one might speculate integrating PSE into the usual 
prescription workflow by making PSE available by prescription-only might alleviate some of the 
burden associated with OTC PSE sales. However, concerns over cost and inconvenience will 
likely exist. The small sample size and limited geographical distribution of the study represents a 
limitation. Additionally, the study was performed via interview and pharmacist responder bias is 
a potential limitation.  
 Students and faculty at the State University of New York at Albany conducted a survey 
of New York pharmacists’ opinions of PSE regulations and presented the results at the 2007 
American Pharmacists Association Annual Meeting.
21
 Drug Topics, a non-peer reviewed trade 
journal, described the research in a 2008 article.
22
 One hundred ninety-three New York State 
pharmacists were surveyed regarding views on PSE regulations, which required logging of 
consumer information for PSE purchases. According to the article, pharmacists in New York felt 
the record-keeping for PSE was unduly burdensome and not reducing illicit methamphetamine 
production, despite 67% of pharmacists feeling there had been a dramatic decrease in PSE 
purchases.
22
 Additionally, average time spent logging information for PSE purchases was 
reported to be 30-38 minutes per week.
22
 Other pharmacist concerns over the PSE regulations 
included lack of a computerized system that could prevent purchases at multiple pharmacies and 
consumers switching to phenylephrine-based products (an alternative OTC nasal decongestant 
which is not utilized in illicit methamphetamine production) to avoid the inconvenience of 
purchasing PSE behind the pharmacy counter without understanding the difference between the 
two products.  
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 The surveys of Australian and New York pharmacists provided a glimpse of the opinions 
of pharmacists regarding OTC PSE regulations requiring logging of PSE purchases. However, 
there are no known studies to date that have assessed healthcare providers’, including 
pharmacists’, opinions of the prescription-only PSE mandate. It is important to understand 
pharmacists’ opinions regarding the proposed prescription-only PSE mandate because 
pharmacists are perceived to be significantly impacted by PSE distribution and appear 
knowledgeable regarding the burdens surrounding PSE distribution. Pharmacists have firsthand 
experience providing PSE to customers with legitimate needs. On-the-other-hand, it is likely that 
many pharmacists, unknowingly or with unsubstantiated suspicion, have provided PSE to 
customers involved in illicit methamphetamine production. Additionally, pharmacists are 
extremely familiar with medication barriers and the impact of disparities on patient care.  
Pharmacists and pharmacy staff are required to record PSE purchases, which takes time and 
leads to questions from patients. PSE regulations can create a strained relationship between 
patients and pharmacists, as patients sometimes view pharmacists as restricting access to PSE. 
Furthermore, pharmacists and pharmacy staff are put in the unique position to deny access to 
PSE, which can cause an uncomfortable situation. Thus, an understanding of pharmacists’ 
opinions regarding methamphetamine precursor regulation is necessary to appreciate the current 
difficulties and perceived efficacy surrounding methamphetamine precursor control and 
implications of proposed legislation to make PSE available by prescription-only. By gaining a 
better understanding of the issues surrounding PSE sales, it is hoped that effective legislation 
may be enacted to reduce methamphetamine production, laboratory incidents and abuse while 
causing the least amount of inconvenience and cost to law abiding citizens.  
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Methods 
This study uses survey methodology to investigate pharmacists’ opinions on the 
effectiveness of current methamphetamine precursor controls, proposed legislation to make PSE 
a legend drug and the anticipated impact of making PSE a legend drug on Kentucky pharmacists’ 
practice and patients. This research has been approved by the University of Kentucky 
Institutional Review Board. Survey questions included perceived efficacy of current 
methamphetamine precursor controls, anticipated impact of proposed legislation to make PSE 
available by prescription-only on individual pharmacy practice and patients, and current opinion 
regarding the proposed legislation (see Appendix A for copy of 2012 Pseudoephedrine Survey 
for Pharmacists). The majority of the questions were fixed response questions. The survey 
utilized various types of response categories, including checklists, Likert-type scales, and 
multiple-choice. A few questions were partial open-ended with the option to select other and 
provide an alternative written answer. One contingency question that was purely open-ended 
asked why respondents were unsure of their support for or opposition to a law requiring a 
prescription to purchase PSE. Additionally, the survey asked open-ended questions about the 
average number of prescriptions filled per day, average number of PSE purchases per day, 
county of practice, description of practice site and year of professional degree.   
A list of all licensed pharmacists from the Commonwealth of Kentucky was obtained 
from the Kentucky Board of Pharmacy for a nominal fee. Pharmacists with an out-of-state 
practice address were removed from the list prior to sampling. A simple random sample of 
pharmacists (n=2000) was drawn using Stata v11.0 software
23
 from the list of all licensed 
pharmacists in the Commonwealth of Kentucky. For this project, all surveys were conducted 
anonymously with no identifying information collected. A cover letter, survey and paid business 
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reply envelope was mailed to the sample of pharmacists on June 11, 2012. A reminder postcard 
was mailed to non-responders on June 27, 2012. Survey collection ended October 5, 2012. 
Returned surveys were entered and maintained in a Research Electronic Data Capture (REDCap) 
survey instrument hosted by the University of Kentucky.
24
 A unique identification number was 
assigned to each responding pharmacist.   
Stata v11.0 statistical software was utilized to analyze the data. Descriptive statistics were 
generated, including frequencies and proportions (See Appendix B). Bivariate analyses were 
conducted using the Chi-squared test and t-test. Multivariate logistic regression was performed to 
investigate the impact of independent variables on pharmacists’ support of the legislation to 
make PSE available by prescription-only. Independent variables and related hypotheses are 
shown in Table 2. 
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Table 2. Independent Variables Utilized in Multivariate Regression and Hypotheses 
Independent Variables Hypotheses 
Chain versus independent 
pharmacist status 
 
Chain pharmacists will be more likely to support the 
legislation  
 
Anticipated impact of legislation on 
time spent on PSE-related activities 
 
Pharmacists anticipating a decrease in time spent on 
PSE-related activities will be more likely to support the 
legislation 
 
Anticipated impact of legislation on 
pharmacy profits 
 
Pharmacists anticipating an increase in profits will be 
more likely to support the legislation 
 
Kentucky region of pharmacy 
practice 
 
Pharmacists practicing in eastern, western and southern 
Kentucky will be more likely to support the legislation 
 
Anticipated impact of legislation on 
methamphetamine abuse and 
laboratory incidents 
 
Pharmacists anticipating the legislation to be effective in 
decreasing methamphetamine abuse and laboratory 
incidents will be more likely to support the legislation 
 
Confidence in identifying patients 
utilizing PSE for a legitimate 
medical purpose 
 
Pharmacists less confident in identifying patients 
utilizing PSE for legitimate medical purposes will be 
more likely to support the legislation  
 
Grams of PSE sold per county 
resident 
 
Pharmacists practicing in counties with more PSE sold 
per county resident will be more likely to support the 
legislation  
 
 
The Kentucky regions were derived from the National Survey on Drug Use and Health 
(NSDUH), which is conducted by the Substance Abuse and Mental Health Services 
Administration (SAMHSA).
25
 The regions are depicted in Appendix C. The grams of PSE sold 
per county resident was obtained from NPLEX.
26
 All other independent variables were derived 
directly from the survey responses.   
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Results 
Descriptive Results 
The 2012 Pseudoephedrine Survey for Pharmacists was returned by 608 pharmacists and 
10 surveys were mailed back with an outdated address, yielding a 30.6% response rate. 
Pharmacists reporting their practice site as “Hospital” or “Other”, as well as pharmacists not 
designating a practice site, were removed from analysis (n=177) because these pharmacists are 
not actively engaged with PSE dispensing. The final sample for analysis included the 431 
pharmacists practicing in a community pharmacy, which included independent, chain, and 
supermarket/mass retailer pharmacy. Chain and supermarket/mass retailer practice sites were 
combined and are hereafter referred to as chain pharmacy for simplicity. Table 3 describes the 
characteristics of the responding community pharmacists and reported practice site 
characteristics.  
Table 3. Characteristics of Responding Pharmacists and Practice Sites 
 
Independent 
Pharmacists 
Chain             
Pharmacists 
All Community 
Pharmacists 
P-value* 
  
Mean 
Std. 
Dev. 
Range Mean 
Std. 
Dev. 
Range Mean 
Std. 
Dev. 
Range 
 
Prescriptions/ 
Day 277.0 148.5 
70–
1000 355.5 173.3 
80–
1000 325.5 168.3 
70–
1000 <0.001 
PSE 
Purchases/Day 4.2 10.2 0–120 13.8 12.6 0–100 10.1 12.6 0–120 <0.001 
Years in 
Practice 23.6 16.1 1–61  18.3 14.4 1–58 20.3 15.3 1–61  <0.001 
N 169 262 431 
 Percentage 39.2% 60.8% 100% 
 * P-values for independent versus chain pharmacists  
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The vast majority, 99.5%, of pharmacists reported being at least somewhat 
knowledgeable regarding the use of PSE in the production of methamphetamine in cladestine 
laboratories. Additionally, a large majority, 97.5%, of pharmacists reported being at least 
somewhat knowledgable regarding the recent proposals to make PSE available by prescription-
only in the Commonwealth of Kentucky (See Figure D).  
Figure D.  
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Pharmacists were questioned regarding perceived efficacy of current PSE controls, 
including the NPLEx electronic tracking system and current quantity limitations, in reducing 
methamphetamine abuse and laboratory incidents. As shown in Figure E, very few pharmacists 
reported that the current PSE controls were “very effective” in reducing methamphetamine abuse 
or laboratory incidents. However, the most frequently selected answer was “somewhat 
effective”. PSE controls were perceived to be more effective at reducing methamphetamine 
abuse than reducing methamphetamine laboratory incidents.  
Figure E.  
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Pharmacists reported a large range in the amount of time required to complete one PSE 
purchase using NPLEx, as shown in Figure F. Answers were distributed among < 1 minute, 1 – 2 
minutes, 2 – 3 minutes, 3 – 4 minutes and > 4 minutes. 
Figure F.
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When questioned about the anticipated efficacy of making PSE a legend drug (i.e. 
requiring a prescription for purchase), approximately 77% of pharmacists reported that the 
legislation would be at least somewhat effective at reducing methamphetamine abuse and 
laboratory incidents, as shown in Figure G. 
Figure G.  
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Pharmacists were questioned regarding the anticipated impact of making PSE available 
by prescription-only on their own pharmacy practice and patients. Nearly half, 48.8%, of 
pharmacists reported an anticipated decrease in time spent on PSE-related activities if PSE were 
to be made available by prescription-only, while 31.7% of pharmacists reported an anticipated 
increase in time spent on PSE-related activities, as shown in Figure H.    
Figure H. 
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Most pharmacists, 47.9%, reported an anticipated neutral financial impact if PSE were to 
be made available by prescription-only. However, a large percentage, 23.8%, reported being 
uncertain of the financial impact on their pharmacy if a prescription were required to obtain PSE 
(see Figure I).  
Figure I.  
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Pharmacists reported that patients would be impacted in a variety of ways if PSE were to 
be made available by prescription-only. A majority, 72.2%, of pharmacists reported patients 
would experience increased time at physicians’ offices obtaining a prescription for PSE. 
Additionally, 69.4% and 67.3% of pharmacists reported limited access to PSE for illicit and 
legitimate users, respectively. Over half of pharmacists reported an anticipated increase in patient 
time spent at the pharmacy obtaining a prescription for PSE and an increase in patient costs (see 
Figure J).  
Figure J.  
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As shown in Figure K, 56.2% of pharmacists support a law to make PSE available by 
prescription-only, while 30.7% of pharmacists oppose the law.  
Figure K.  
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Prescription Electronic Reporting (KASPER) system. Additionally, several comments stated that 
pharmacists should use better professional judgment and deny PSE to those who are thought to 
be using PSE illicitly. Comments reasoned that pharmacists asking more questions and using 
better professional judgment would ultimately result in fewer illicit producers coming to the 
pharmacy to purchase PSE. Finally, concern over increased criminal activity (robberies and 
threatening behavior towards pharmacy staff) if PSE were made prescription-only was discussed 
in several comments. 
Figure L.  
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Figure M. 
 
 
Table 4 breaks down pharmacists’ support or opposition of the legislation by region. Regions 1 
and 3, which include northern Kentucky, Lexington and Louisville, remain split on the 
legislation. However, the remaining regions, which include western, eastern and southern 
Kentucky, largely support the legislation. The vast majority, 86.0%, of pharmacists in southern 
Kentucky (region 6) support the legislation.  
Table 4. Pharmacists Support or Opposition of Legislation Broken Down by Region  
Regions 
 1 2 3 4 5 6 Total 
Oppose Legislation 50 13 32 11 12 8 126 
Support Legislation 60 32 35 27 27 49 230 
Total 110 45 67 38 39 57 356 
Percentage Pharmacists 
Supporting 
54.5% 71.1% 52.2% 71.1% 71.1% 86.0% 64.6% 
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the t-test was repeated to control for size of the pharmacy by dividing reported PSE sales per day 
by the reported number of prescriptions per day times 100% (t(398) = -7.5016, p = <0.001). 
Thus, chain pharmacies are selling significantly more PSE than independent pharmacies when 
controlling for pharmacy size. Furthermore the independent group t-test was performed to 
compare the means of independent versus chain pharmacist reported prescriptions per day 
(t(411) = -4.7077, p = <0.001) and to compare the mean number of years in practice (t(423) = 
3.5356, p = <0.001).  
A 2x2 chi-squared test was performed to compare the anticipated impact on time spent on 
PSE-related activities if PSE were available by prescription-only (increase or decrease in time 
spent on PSE-related activities, see Figure H) between independent and chain pharmacists. There 
was no significant difference between independent and chain pharmacists’ anticipated impact on 
time spent on PSE-related activities if PSE were available by prescription-only, p = 0.336. A 2x2 
chi-squared test was also performed to compare the anticipated impact on profits if PSE were 
available by prescription-only (increase or decrease in profit, see Figure I) between independent 
and chain pharmacists. There was no significant difference between independent and chain 
pharmacists’ anticipated impact on profit if PSE were available by prescription-only, p = 0.744. 
Logistic regression was conducted to determine the impact of selected independent 
variables on pharmacists’ support of the proposed legislation to make PSE available by 
prescription-only. Regression results are shown in Table 5.  
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Table 5. Logistic Regression Model for Pharmacists Supporting the Legislation to Make PSE 
Available by Prescription-only  
Support Legislation to Make PSE 
Available by Prescription-only  
Odds 
Ratio 
Robust Std. 
Error 
95% Confidence 
Interval 
Chain Pharmacists 2.90* 1.22 1.27 – 6.60 
Anticipated PSE Rx Only Impact on Time 
Spent on PSE Activities – Increase in Time 
   
No Change in Time 5.09* 2.75 1.77 – 14.65 
Decrease in Time  10.57* 4.71 4.42 – 25.30 
Not Applicable  1.02e7* 1.37e7 7.24e5 – 1.43e8 
Anticipated PSE Rx Only Impact on 
Pharmacy Profits – Reduced Profits 
   
Increased Profits 9.45* 7.98 1.80 – 49.5 
Neutral Financial Impact 4.53* 2.34 1.64 – 12.45  
Uncertain 3.78* 2.11 1.27 – 11.26 
Not Applicable  3.86e-6* 6.02e-6 1.82e-7 – 8.2e-5 
Regions – Bluegrass, Comprehend, North 
Key 
   
Kentucky River, Mountain, Pathways 4.57* 2.86 1.34 – 15.59 
Seven Counties 1.89 1.02 0.66 – 5.44 
Communicare and River Valley 8.17* 6.52 1.71 – 39.03 
Four Rivers and Pennyroyal  4.04* 2.53 1.19 – 13.79 
Adanta, Cumberland River, Lifeskills 7.99* 5.01 2.34 – 27.30 
Perceived Efficacy of Making PSE Rx 
Only on Reducing Methamphetamine 
Abuse – Not Effective  
   
Somewhat ineffective 1.52 1.38 0.26 – 9.02 
Somewhat effective 8.22* 6.07 1.94 – 34.93 
Very effective 34.05* 30.49 5.89 – 196.97 
Perceived Efficacy of Making PSE Rx 
Only on Reducing Methamphetamine Lab 
Incidents – Not Effective  
   
Somewhat ineffective 2.26 2.07 0.38 – 13.55 
Somewhat effective 2.56 1.69 0.70 – 9.32 
Very effective 8.47* 6.98 1.68 – 42.60 
 No opinion 4.92 5.47 0.56 – 43.54 
Confidence in Identifying Patients Using 
PSE for a Legitimate Purpose – Extremely 
Confident 
   
Somewhat confident 0.67 0.28 0.30 – 1.54 
Not confident 0.81 0.72 0.14 – 4.58 
Not applicable 0.81 1.16 0.05 – 13.54 
Grams PSE per County Resident Sold 0.51 0.36 0.13 – 1.99 
Note: * P-value <0.05; “Rx-only” refers to the proposed prescription-only mandate 
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 The logistic regression results showed that chain pharmacists were 2.9 times more likely 
to support the legislation to make PSE available by prescription-only versus independent 
pharmacists. Pharmacists that anticipated no change in time related to PSE activities or a 
decrease in time related to PSE activities if PSE were to be available by prescription-only were 
5.09 and 10.57 times more likely to support the legislation, respectively. Anticipated impact on 
pharmacy profits was also significantly related to pharmacists’ support of the legislation 
requiring a prescription to purchase PSE.  Pharmacists reporting an anticipated increase in profits 
were 9.45 times more likely to support the legislation and pharmacists reporting a neutral 
financial impact were 4.53 times more likely to support the legislation versus pharmacists 
reporting an anticipated decrease in profits. The region of pharmacy practice significantly 
impacted pharmacists’ support of the legislation. Compared to pharmacists practicing in region 
1, which includes northern Kentucky and Lexington (see Appendix C for map), pharmacists 
practicing in regions 2, 4, 5, and 6 were 4.57, 8.17, 4.04, 7.99 times more likely to support the 
legislation, respectively. Region 3, which includes Louisville, was not significant and reported 
results more similar to region 1.  
Pharmacists anticipating the legislation to be somewhat effective or very effective at 
reducing methamphetamine related abuse were 8.22 and 34.05 times more likely to support the 
legislation versus pharmacists reporting that the legislation would not be effective at all. The 
results were not significant for anticipated reduction in methamphetamine lab incidents, except 
when pharmacists reported the legislation to be very effective in reducing lab incidents. 
Pharmacists anticipating the new legislation to be very effective at reducing lab incidents were 
8.47 times more likely to support the legislation versus pharmacists anticipating the legislation to 
not be effective at all. Interestingly, pharmacists’ reported confidence in identifying patients 
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utilizing PSE for a legitimate medical purpose is not significantly related to support of the 
legislation. Furthermore, grams of PSE sold per county resident is not significantly related to 
support of the legislation. 
 
Discussion 
 There is currently very little data available about the opinions of healthcare providers, 
specifically pharmacists, regarding methamphetamine precursor chemical controls. The only 
available studies investigated the opinions of Australian and New York pharmacists regarding 
OTC PSE regulations requiring logging of PSE purchases.
20,22
 Furthermore, studies funded by 
the Asthma and Allergy Foundation of America (AAFA) and the Consumer Health Products 
Association (CHPA), which are organizations that largely oppose the proposed prescription-only 
PSE legislation, have shown that a majority of consumers oppose legislation requiring a 
prescription to purchase PSE and that the legislation would unduly burden law-abiding 
citizens.
18,19
 This study aims to gain a better understanding of Kentucky pharmacists’ opinions of 
current precursor controls and proposed legislation to make PSE available by prescription-only.  
 Hospital and specialty pharmacists were excluded from the analysis in order to focus on 
pharmacists practicing in a community pharmacy setting, including independent and chain 
pharmacies. Community pharmacists are more visibly impacted by PSE controls. There were 
significant differences between independent and chain pharmacists in terms of the reported 
number of prescriptions filled per day, number of PSE purchases per day and the number of 
years in practice. Significantly more PSE was reported to be sold on a daily basis in chain 
pharmacies, 13.8 purchases per day versus 4.2 purchases per day. A potential reasoning could be 
the sheer difference in store size and the number of customers entering the pharmacy per day; 
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independent pharmacists reported filling an average of 277 prescriptions per day versus 355.5 
prescriptions per day in chain pharmacies. On-the-other-hand, several written comments 
referenced the push from chain pharmacy management to sell PSE, “Independent pharmacists 
are more reserved in selling PSE to patients - chain pharmacists are impacted by store 
managers/profit”. It is possible that independent pharmacists feel more empowered to develop 
their own store policies in the best interest of patients regarding PSE purchases, while chain 
pharmacists are required to follow corporate policies aimed at increasing profits. Additionally, 
chain pharmacists were 2.90 times more likely to support the legislation to make PSE available 
by prescription-only versus independent pharmacists.  
 The anticipated efficacy of the proposed legislation to require a prescription in order to 
purchase PSE was reported by approximately 77% of pharmacists to be at least somewhat 
effective in reducing methamphetamine abuse and laboratory incidents. Despite the large number 
of pharmacists reporting at least some anticipated efficacy of the proposed legislation requiring a 
prescription to purchase PSE, 56.2% of pharmacists reported supporting a law to make PSE 
available by prescription-only and 30.7% of pharmacists reported opposition to the law. The 
survey results showed that the majority of pharmacists, approximately 68%, opposing the 
proposed legislation reported doing so based on patient specific factors, including increased 
patient inconvenience and cost. Only 23.5% of the pharmacists opposing the legislation selected 
anticipated inefficacy of the law as the primary reason for opposing the law. On-the-other-hand, 
the primary reason pharmacists reported supporting a law requiring a prescription for PSE was 
decreased risk of methamphetamine abuse and the second most common reason was the 
anticipated decreased burden on the pharmacy. Additionally, the logistic regression model 
showed that pharmacists’ anticipated efficacy of making PSE available by prescription-only in 
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reducing methamphetamine abuse is significantly related to supporting the legislation. 
Pharmacists reporting the legislation to be effective in reducing methamphetamine abuse are 
more likely to support the legislation.   
An additional interesting result of the survey involves the time requirements for PSE 
controls. Pharmacists reported a large range in the time requirements to complete one PSE 
purchase using the electronic tracking system, NPLEx. Answers varied from less than one 
minute to greater than four minutes to complete one purchase. A potential reason for the wide 
variation in reported time to complete one PSE purchase is that pharmacists are not actually 
completing PSE purchases and are not fully aware of the time requirement. It is likely that 
pharmacy technicians and interns perform the majority of the PSE purchases. An alternative 
reason for the wide variation is differing time saving technology among pharmacies. Some 
pharmacies are able to simply scan identification cards versus manually entering in patient 
information into the NPLEx website. Additionally, pharmacists were asked to report the 
anticipated time impact of making PSE available by prescription-only. The majority of 
pharmacists, 48.8%, reported an anticipated decrease in time spent on PSE-related activities if 
PSE were to be available by prescription-only and 31.7% of pharmacists reported an anticipated 
increase in time spent on PSE related activities. However, it has been estimated that the average 
prescription takes approximately eight minutes to be filled, yet approximately 88% of pharmacist 
reported that one PSE purchase took less than four minutes.
27
 It appears that a significant portion 
of pharmacists either view prescriptions as taking less time to fill than the true time to fill a 
prescription or pharmacists perceive PSE purchases to take a more significant amount of time 
than reported according to the survey results as shown in figure H. One potential reasoning for 
the disconnect is that PSE purchases represent an interruption in the normal workflow of the 
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pharmacy, which predominately involves filling prescriptions. None-the-less pharmacists were 
more likely to support the legislation if they anticipated a decrease in time spent on PSE-related 
activities.  
The logistic regression analysis of pharmacists’ support of the legislation to make PSE 
available by prescription showed a significant impact of pharmacy practice region on support for 
the legislation. Pharmacists practicing in western, eastern and southern Kentucky were 
significantly more likely to support the proposed legislation. The odds ratios for these regions 
ranged from approximately 4 to 8 when comparing to the northern Kentucky and Lexington 
region. Additionally, the descriptive statistics showed that roughly 53% of pharmacists in the 
northern Kentucky, Lexington and Louisville regions support the legislation while approximately 
71% of pharmacists in eastern and western Kentucky support the legislation. Finally, 86% of 
pharmacists in southern Kentucky support the legislation. Traditionally, methamphetamine 
production has been associated with western and south central Kentucky, and indicators of 
methamphetamine are increasing in eastern Kentucky.
14
 The pharmacists practicing in areas most 
strongly associated with methamphetamine appear to be more likely to support the legislation to 
make PSE available by prescription-only.  
Finally, two independent variables were surprisingly not found to have significant impact 
on pharmacists’ support of the proposed legislation to make PSE available by prescription-only. 
Whether or not a pharmacist is confident in identifying patients utilizing PSE for a legitimate 
medical purpose was not found to be significantly related to the support of the legislation. The 
hypothesis that pharmacists not confident in identifying patients utilizing PSE for a legitimate 
medical purpose would be more likely to support the legislation was not supported by the logistic 
regression model. Additionally, pharmacists’ support of the legislation was not found to be 
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significantly related to the amount of PSE (grams) sold per county resident. Again, the 
hypothesis that pharmacists practicing in counties selling more PSE per county resident would be 
more likely to support the legislation was not supported by the logistic regression model. It is 
possible that pharmacists are simply not aware of how much PSE is sold per county resident in 
comparison to other counties.  
 
Limitations 
 Several limitations exist in regards to this capstone project. The survey response rate, 
while respectable, only represents 30.6% of the total pharmacist sample surveyed. Additionally, 
the sample size is relatively small (n=608) and was further reduced to n=431 when hospital 
pharmacists and pharmacists practicing in “other” settings were excluded from analysis. The 
sample for analysis, while representing strong internal validity, lacks external validity as only 
Kentucky pharmacists practicing in a community pharmacy setting were included.  
 Some of the capstone limitations are simply due to the research survey methodology. The 
researcher developed the survey questions and it is possible that important response categories 
might have been missing from fixed-choice questions. Additionally, responses are mostly 
inflexible and require respondents to select one answer and do not provide much opportunity for 
discussion or additional details. Another potential issue with survey methodology is response 
bias and self-selection bias. Pharmacists choosing to respond to the survey may be inherently 
different from pharmacists not choosing to respond. Unfortunately, given the design of the study, 
it is not possible to explore potential differences between responders and non-responders. 
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Conclusion and Implications  
  In conclusion, the results of the 2012 Pseudoephedrine Survey for Pharmacists have shed 
some light on the controversial proposed legislation to make PSE available by prescription-only.  
Despite current federal legislation and increased Kentucky quantity restrictions and NPLEX 
tracking, methamphetamine abuse remains a significant problem in Kentucky. This survey was 
conducted in order to gain a better understanding of the issues surrounding the sale of PSE from 
the health care provider at the frontline – the pharmacist. By gaining a better understanding of 
the issues surrounding the sale of PSE it is hoped that effective, future legislation may be enacted 
to reduce methamphetamine production, laboratory incidents and abuse yet result in the least 
amount of inconvenience and cost to law abiding citizens. 
The survey results showed that 56.2% of Kentucky pharmacists practicing in a 
community pharmacy support the proposed legislation to make PSE available by prescription-
only, 30.7% of pharmacists oppose the legislation and 13.1% of pharmacists are unsure. 
Furthermore, independent and chain pharmacists significantly differ in the average number of 
prescriptions filled per day, number of PSE purchases per day and the number of years in 
practice. Practice site significantly impacts support for the proposed legislation with chain 
pharmacists being 2.90 times more likely to support the legislation to make PSE prescription-
only. One possible explanation for this difference is that independent pharmacists may exhibit 
more autonomy in the decision making process to sell or not sell PSE to potential customers. 
Additional factors that influence pharmacist support of the legislation include: anticipated impact 
of making PSE prescription-only on time spent on PSE-related activities and pharmacy profits, 
Kentucky region of pharmacy practice, and anticipated impact of making PSE prescription-only 
on methamphetamine abuse and laboratory incidents. Kentucky region of pharmacy practice 
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appears to have a large impact on pharmacist support of the legislation. Regions associated more 
strongly with methamphetamine such as western, eastern, and southern Kentucky appear to more 
strongly support the proposed legislation.  
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Appendix B: Descriptive Survey Results  
 
How knowledgeable are you regarding the recent proposals to make PSE a legend 
(unscheduled) drug available by prescription-only in the Commonwealth of Kentucky?  
 Frequency Percentage (%) 
Very knowledgeable 204 47.4 
Somewhat knowledgeable 215 50.0 
I have no knowledge 11 2.6 
Total Respondents  430  
  
To what extent do you believe the current National Precursor Log Exchange (NPLEx), formerly 
MethCheck, is effective at reducing methamphetamine-related abuse? 
 Frequency Percentage (%) 
Not effective at all 74 17.2 
Somewhat ineffective 91 21.2 
Somewhat effective 239 55.6 
Very effective 16 3.7 
I have no opinion  10 2.3 
Total Respondents  430  
 
To what extent do you believe the current National Precursor Log Exchange (NPLEx), formerly 
MethCheck, is effective at reducing methamphetamine-related lab incidents? 
 Frequency Percentage (%) 
Not effective at all 94 22.2 
Somewhat ineffective 93 22.0 
Somewhat effective 204 48.2 
Very effective 12 2.8 
I have no opinion  20 4.7 
Total Respondents  423  
 
 
 
How aware are you regarding the use of PSE in the production of methamphetamine in 
clandestine labs? 
 Frequency Percentage (%) 
Very aware 377 87.7 
Somewhat aware 51 11.9 
I am not aware 2 0.5 
Total Respondents   430  
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On average, how long does it currently take your pharmacy to use NPLEx to complete one PSE 
purchase?  
 Frequency Percentage (%) 
< 30 seconds 26 6.1 
30 seconds – 1 minute 59 13.8 
1 – 2 minutes 107 25.1 
2 – 3minutes 94 22.0 
3 – 4 minutes 66 15.5 
> 4 minutes  49 11.5 
N/A  26 6.1 
Total Respondents 427  
 
To what extent do you believe the current retail sales quantity restriction of PSE (9 grams per 
month) is effective at reducing methamphetamine-related abuse? 
 Frequency Percentage (%) 
Not effective at all 116 27.0 
Somewhat ineffective 113 26.3 
Somewhat effective 179 41.6 
Very effective 15 3.5 
I have no opinion  7 1.6 
Total Respondents  430  
 
To what extent do you believe the current retail sales quantity restriction of PSE (9 grams per 
month) is effective at reducing methamphetamine-related lab incidents? 
 Frequency Percentage (%) 
Not effective at all 119 28.1 
Somewhat ineffective 112 26.4 
Somewhat effective 167 39.4 
Very effective 11 2.6 
I have no opinion  15 3.5 
Total Respondents  424  
 
To what extent do you believe making PSE a legend drug (unscheduled) available by 
prescription-only would be effective at reducing methamphetamine-related abuse? 
 Frequency Percentage (%) 
Not effective at all 55 12.8 
Somewhat ineffective 43 10.0 
Somewhat effective 167 38.9 
Very effective 163 38.0 
I have no opinion  1 0.2 
Total Respondents  429  
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To what extent do you believe making PSE a legend drug (unscheduled) available by 
prescription-only would be effective at reducing methamphetamine-related lab incidents? 
 Frequency Percentage (%) 
Not effective at all 52 12.2 
Somewhat ineffective 41 9.6 
Somewhat effective 174 40.9 
Very effective 153 35.9 
I have no opinion  6 1.4 
Total Respondents  426  
 
If PSE were to be available by prescription-only, how significant of an impact on your 
pharmacy would you anticipate?  
 Frequency Percentage (%) 
Increase in time spent on PSE 
related activities  
132 30.9 
No change in time spent on PSE 
related activities  
81 19.0 
Decrease in time spent on PSE 
related activities  
203 47.5 
Not applicable for my practice 
setting 
11 2.6 
Total Respondents  427  
  
If PSE were to be available by prescription-only, what financial impact would you anticipate 
to your pharmacy?  
 Frequency Percentage (%) 
Reduced profits  82 19.1 
Increased profits  37 8.6 
Neutral financial impact  201 46.7 
Uncertain  100 23.3 
Not applicable for my practice 
setting  
10 2.3 
Total Respondents  430  
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How confident do you feel in your ability to identify your patients who are using PSE for a 
legitimate medical purpose?  
 Frequency Percentage (%) 
Extremely confident  132 31.1 
Somewhat confident  256 60.2 
Not confident  28 6.6 
Unknown  4 0.9 
Not applicable for my practice 
setting  
5 1.2 
Total Respondents  425  
  
How would making PSE available by prescription-only impact your patients? Check all that 
apply.  
 Frequency  Percentage (%) 
Increase in patient time spent at 
physician’s office obtaining 
prescription for PSE  
311 72.2 
Increase in patient time spent in 
the pharmacy getting a 
prescription for PSE filled  
245 56.8 
Increase in financial costs for 
patients  
240 55.7 
Limit access to PSE for those 
with legitimate needs  
290 67.3 
Limit access to PSE for those 
attempting to illegally produce 
methamphetamine  
299 69.4 
Reduce risk of 
methamphetamine abuse  
222 51.5 
Reduce risk of injury sustained 
from unsafe methamphetamine 
clandestine labs  
212 49.2 
No impact  3 0.7 
 
At this time, do you support or oppose a law that would require a prescription in order to 
obtain PSE?  
 Frequency Percentage (%) 
Support  240 56.2 
Oppose  131 30.7 
Unsure  56 13.1 
Total Respondents 427  
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Please indicate the primary reason why you support a law that would require a prescription 
in order to obtain PSE? Select one.  
 Frequency Percentage (%) 
Reduces risk of 
methamphetamine abuse  
94 39.0 
Reduces risk of injury from 
clandestine lab  
11 4.6 
Decreased burden on my 
pharmacy dealing with people 
trying to purchase PSE behind 
the counter  
55 22.8 
Current laws requiring electronic 
tracking of PSE are ineffective  
42 17.4 
Restricts access to only those 
who need the medication  
35 14.5 
Other  4 1.7 
Total Respondents 241  
 
Please indicate the primary reason why you would oppose a law that would require a 
prescription in order to purchase PSE? Select one.  
 Frequency Percentage (%) 
Increased cost to patients  43 31.6 
Increased inconvenience to 
patients  
50 36.8 
Law would be ineffective  32 23.5 
Increased burden on my 
pharmacy to fill additional 
prescriptions  
2 1.5 
Other  9 6.6 
Total Respondents  136  
 
On average, how many prescriptions does your pharmacy fill each day? 
Mean Std. Dev. Median Range 
325.5 168.3 300 70 - 1000 
  Total Respondents  411 
 
On average, how many PSE purchases are made at your pharmacy each day? 
Mean Std. Dev. Median Range 
10.1 12.6 5 0 - 120 
  Total Respondents  408 
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What best describes your practice site? Select one.  
 Frequency Percentage (%) 
Independent Pharmacy  169 39.2 
Chain/ Supermarket/ Mass 
Retailer Pharmacy  
262 60.8 
Total Respondents 431  
 
Number of Years in Practice. (Derived from “In what year did you receive your professional 
degree?”) 
Mean Std. Dev. Median Range 
20.3 15.3 18 1 - 61 
  Total Respondents  423 
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Appendix C: Kentucky Regions
25
  
 
